Research Roundup: Sept 20, 2021
- Lex Pelger
- Sep 19, 2021
- 2 min read
Best of the Week...
Zynerba presents their new Phase 2 data on their transdermal CBD gel for treating autism
Longer Term Tolerability and Efficacy of ZYN002 Cannabidiol Transdermal Gel in Children and Adolescents with Autism Spectrum Disorder (ASD): An Open-Label Phase 2 Study
This review takes a deep dive into the data on CBD for Alzheimer’s disease
Understanding the Modulatory Effects of Cannabidiol on Alzheimer’s Disease
A review of the effects of cannabis & the cannabinoids like CBD on athletic performance
Cannabis and Athletic Performance
In humans, younger people have more CB1 receptors in their muscle than older people – but you can increase your cannabinoid receptor levels with resistance exercise
Cannabinoid receptor 1 expression is higher in muscle of old vs. young males, and increases upon resistance exercise in older adults
A review of the use of cannabinoids for skin health
Topical Use of Cannabis sativa L. Biochemicals
American Family Physician reviews the positive evidence on melatonin for sleep
Melatonin to Treat Insomnia in Older Adults
Dr. Piomelli reviews the promise of endocannabinoid-based therapies
Endocannabinoid-Based Therapies
Also, you watch our interview with Dr. Piomelli here.
Clinical Studies & Reviews of CBD & the Endocannabinoid System (ECS)
A review of the use of cannabinoids in dentistry with a special focus on CBD
The Current and Potential Application of Medicinal Cannabis Products in Dentistry
A case report of a man with ALS & severe itching who used oral cannabinoids to treat his skin condition
Cannabinoids for the treatment of refractory neuropathic pruritus in amyotrophic lateral sclerosis: A case report
In humans with COVID-19, a certain genetic variant of the CB2 receptor leads to worse outcomes
Functional variation (Q63R) in the cannabinoid CB2 receptor may affect the severity of COVID-19: a human study and molecular docking
A review of the other receptors that may one day be known as endocannabinoid receptors (hattip to Stuart Tomc)
Endocannabinoid signaling pathways: beyond CB1R and CB2R
A review of using the cannabinoids to treat the pain of MS
Efficacy, tolerability and safety of cannabinoids for management of pain in adult patients with multiple sclerosis: A systematic review and meta-analysis
Preclinical Research & Cannabinoid Chemistry
The CB2 receptor is a key pathway to control homeostasis of our brain’s microglia (immune cells that respond to potential threats) Cannabinoid receptor 2 is necessary to induce toll-like receptor-mediated microglial activation https://pubmed.ncbi.nlm.nih.gov/34499767/ In a mouse model of inflammatory pain, treatment with JNK (a novel pain inhibitor) works via the CB2 receptor in females & by both the CB1 & CB2 receptor in males Sex and dose-dependent antinociceptive effects of the JNK (c-Jun N-terminal kinase) inhibitor SU 3327 are mediated by CB2 receptors in female, and CB1/CB2 receptors in male mice in an inflammatory pain model https://www.sciencedirect.com/science/article/abs/pii/S0361923021002677 In mice with no CB1 receptors in their liver cells, they saw no difference in their response to a high fat diet & concluded that the CB1 receptors had no direct role in the development of nonalcoholic fatty liver disease or liver fibrosis Cannabinoid receptor-1 signaling in hepatocytes and stellate cells does not contribute to NAFLD https://pubmed.ncbi.nlm.nih.gov/34499619/ In a fruit fly model of depression, an extract made from hemp seeds alleviated depression symptoms & modulated the circadian rhythm (hattip to Stuart Tomc, who somehow found this 3 months before it’s publication date)
Anti-depressant effects of ethanol extract from Cannabis sativa (hemp) seed in chlorpromazine-induced Drosophila melanogaster depression model https://pubmed.ncbi.nlm.nih.gov/34362287/
Comments